Hemab Therapeutics Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Hemab Therapeutics Holdings, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-95.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 82% of Healthcare companies in United States.
Cash Cushion Ratio
+11%Cash, after subtracting all debt, equals 11% of its market value (net cash).
Higher than 52% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Hemab Therapeutics Holdings, Inc. made a loss over the last year. Hemab Therapeutics Holdings, Inc. owes $0.03 for every $1 it owns. Hemab Therapeutics Holdings, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossHemab Therapeutics Holdings, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.58The share price is 3.58 times Hemab Therapeutics Holdings, Inc.'s book value per share, higher than 61% of Healthcare companies in United States.
Market cap
$1.6 BThe total market value of all of Hemab Therapeutics Holdings, Inc.'s shares at today's price (share price × number of shares), larger than 70% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$454 MWhat Hemab Therapeutics Holdings, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$9.72Net worth divided by the number of shares. The share price of $34.82 is 3.6 times this, which is the P/B above.
Owes vs Owns
0.03×Hemab Therapeutics Holdings, Inc. owes $0.03 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Dividend yield
NoneHemab Therapeutics Holdings, Inc. does not currently pay a dividend.
Profit growth
LossHemab Therapeutics Holdings, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashHemab Therapeutics Holdings, Inc. held $184 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Hemab Therapeutics Holdings, Inc.: $1.6 B ÷ $454 M (30 Jun 2026) = 3.6.
How much does Hemab Therapeutics Holdings, Inc. owe compared with what it owns?
Hemab Therapeutics Holdings, Inc. owes $0.03 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Does Hemab Therapeutics Holdings, Inc. pay a dividend?
No. Hemab Therapeutics Holdings, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.